Research and development initiatives have long acknowledged that patient participation in clinical research is driven by “hope for a cure” as a key incentive
Patient reported outcomes, subgroup analyses, “exit” interviews at study conclusions, help contextualize the value of trial data within a scientific, clinical, and humanistic framework
Within oncology indications particularly, selective patient targeting, innovative trial designs to accelerate approval, and assessments that reflect how patients “feel, function or survive” are highlighted as distinguishing characteristics.
The Patient Selection Problem: Current biomarker-based strategies identify <30% of likely responders, leading to high failure rates and inefficient trial designs.
The SAGE Oncotest Advantage: A best-in-class ex vivo functional profiling platform that tests patient-derived tumor cells directly against the investigational drug to identify true responders.
Smarter Trial Design: Incorporating functional profiling to enrich responders into the study, thereby reducing required sample size while increasing clinical trial success rates
